AN2 Therapeutics, Inc.

This Quarterly Report on Form 10-Q (“Form 10-Q”) contains forward-looking statements. All statements other than statements of historical facts contained in this Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical and nonclinical studies and clinical trials, results of preclinical and nonclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Form 10-Q include, but are not limited to, statements about:

▪

the initiation, timing, progress, and results of our preclinical and nonclinical studies and clinical trials, and our research and development programs, including the manufacture of clinical trial material and drug product for launch;

▪

the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;

▪

▪

our use of the net proceeds from financing activities;

▪

the outcome of potential interactions with the U.S. Food and Drug Administration (“FDA”) regarding future development of our product candidates;

▪

our ability to commence potential future studies of our product candidates in new patient populations, which regulatory authorities may not allow or authorize or may delay allowing or authorizing;

▪

the translation of our preclinical results and data and early clinical trial results, in particular relating to safety, efficacy and durability, into future clinical trial results;

▪

▪

our ability to advance our product candidates we may develop into, and successfully complete, clinical trials;

▪

the timing of and our ability to obtain and maintain regulatory approvals for our product candidates we may develop;

▪

the commercialization of our product candidates we may develop, if approved;

▪

the ability of our product candidates, if approved, to successfully compete with other therapies, including therapies currently in development;

▪

the size of the market opportunity for product candidates we may develop in each of the diseases we target;

▪

the implementation of our business model, strategic plans for our business, and our product candidates we may develop;

▪

the scope of protection we are able to establish and maintain for intellectual property rights covering product candidates;

▪

the potential post-approval marketing exclusivities that may be granted to product candidates based upon certain regulatory designations, and other non-patent exclusivities in the United States and elsewhere;

▪

our ability to identify additional product candidates and advance them into clinical development;

▪

our financial performance;

▪

▪

our expectations regarding the impact of inflation, macroeconomic conditions and geopolitical conflicts on our business and operations, including on our manufacturing suppliers, collaborators, contract research organizations (“CROs”) and employees; and

▪

our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects and these forward-looking statements are not guarantees of future performance, or development. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of risks, uncertainties, and assumptions described in the section titled “Risk Factors” and elsewhere in this Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, or otherwise.